Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization

被引：0
|
作者：
Renaud Sabatier
Pascal Finetti
Arnaud Guille
José Adelaide
Max Chaffanet
Patrice Viens
Daniel Birnbaum
François Bertucci
机构：
[1] Institut Paoli-Calmettes (IPC),Department of Molecular Oncology, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm
[2] Institut Paoli-Calmettes (IPC),Department of Medical Oncology
[3] Université Aix-Marseille,Faculté de Médecine
来源：
Molecular Cancer | / 13卷
关键词：
Breast cancer; Claudin-low; Molecular profiling; Prognosis; Response to chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters?
    Madaras, Lilla
    Balint, Nora
    Gyorffy, Balazs
    Tokes, Anna-Maria
    Barshack, Iris
    Yosepovich, Ady
    Friedman, Eitan
    Paluch-Shimon, Shani
    Zippel, Dov
    Baghy, Kornelia
    Timar, Jozsef
    Kovalszky, Ilona
    Kulka, Janina
    Szasz, Attila Marcell
    PATHOBIOLOGY, 2016, 83 (01) : 1 - 12
  • [42] Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype
    Miguel Rito
    Fernando Schmitt
    António E. Pinto
    Saudade André
    Virchows Archiv, 2014, 465 : 185 - 191
  • [43] Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
    Leanne Stalker
    James Pemberton
    Roger A Moorehead
    Cancer Cell International, 14
  • [44] ALDH1A3-inducible RARRES1 is a tumor suppressor in triple-negative breast cancer and is methylated in claudin-low breast cancers
    Coyle, Krysta M.
    Murphy, Patrick
    Vidovic, Dejan
    Dean, Cheryl A.
    Thomas, Margaret L.
    Clements, Derek
    Sultan, Mohammad
    Vaghar-Kashani, Ahmad
    Giacomantonio, Carman
    Helyer, Lucy
    Weaver, Ian
    Gujar, Shashi
    Lee, Patrick W. K.
    Marcato, Paola
    CANCER RESEARCH, 2016, 76
  • [45] Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer
    Vick, Sarah C.
    Taylor, Nicholas A.
    Iglesia, Michael D.
    Brickey, W. June
    Carey, Lisa A.
    Midkiff, Bentley R.
    McKinnon, Karen P.
    Reisdorf, Shannon
    Parker, Joel S.
    Perou, Charles M.
    Vincent, Benjamin G.
    Serody, Jonathan S.
    CANCER RESEARCH, 2017, 77
  • [46] Loss of the hippo pathway scaffold "Kibra" in a mouse model of human claudin-low breast cancer
    Knight, Jennifer F.
    Lesurf, Robert
    Saleh, Sadiq M.
    Davis, Ryan R.
    Zhao, Hong
    Zuo, Dongmei
    Cardiff, Robert D.
    Gregg, Jeff
    Hallett, Michael
    Park, Morag
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [47] The identification of highly upregulated genes in claudin-low breast cancer through an integrative bioinformatics approach
    Zayed, Hatem
    COMPUTERS IN BIOLOGY AND MEDICINE, 2020, 127
  • [48] Claudin-Low Breast Cancer: A Novel Subtype Associated with Basal-Like Phenotype and Metaplastic Breast Cancer
    Lu, S.
    Singh, K.
    Mangray, S.
    Tavares, R.
    Noble, L.
    DeLellis, R. A.
    Resnick, M.
    Yakirevich, E.
    LABORATORY INVESTIGATION, 2011, 91 : 52A - 53A
  • [49] Lunatic Fringe and p53 cooperatively prevent development of claudin-low breast cancer
    Chung, Wen-Cheng
    Zhang, Shubing
    Xu, Keli
    CANCER RESEARCH, 2016, 76
  • [50] Analysis of the expression of claudin-3,-4,-7 and E-cadherin in breast cancer: are they surrogates for the claudin-low subtype?
    Tokes, A-M
    Szasz, A. M.
    Kovacs, A. K.
    Juhasz, E.
    Nemeth, Z.
    Baranyai, Z.
    Madaras, L.
    Kulka, J.
    CANCER RESEARCH, 2012, 72
12345